These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9543121)

  • 41. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.
    Duntas LH; Stathatos N
    Endocrine; 2011 Jun; 39(3):199-204. PubMed ID: 21442382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type Ib.
    Tollin SR; Perlmutter S; Aloia JF
    J Bone Miner Res; 2000 Jul; 15(7):1412-6. PubMed ID: 10893692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcimimetics--new drugs with the potential to control hyperparathyroidism.
    Ott SM
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1080-2. PubMed ID: 9543121
    [No Abstract]   [Full Text] [Related]  

  • 44. Nonoperative management of hyperparathyroidism: present and future.
    Weigel RJ
    Curr Opin Oncol; 2001 Jan; 13(1):33-8. PubMed ID: 11148683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
    Drüeke TB; Ritz E
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of estrogens and related compounds in the management of primary hyperparathyroidism.
    Marcus R
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N146-9. PubMed ID: 12412792
    [No Abstract]   [Full Text] [Related]  

  • 47. Therapeutic use of calcimimetics.
    Hebert SC
    Annu Rev Med; 2006; 57():349-64. PubMed ID: 16409154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Basic and clinical aspects of calcimimetics. Calcimimetic is indicated for patients with surgically uncontrollable hyperparathyroidism].
    Tominaga Y
    Clin Calcium; 2008 Jan; 18(1):67-71. PubMed ID: 18175874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calcimimetics and calcilytics--fooling the calcium receptor.
    Steddon SJ; Cunningham J
    Lancet; 2005 Jun 25-Jul 1; 365(9478):2237-9. PubMed ID: 15978932
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.